A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)
The purpose of this study is to compare the effects on patients with metastatic melanoma of
taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the
same type of agent continuously. Researchers want to see if the two ways of giving this type
of treatment work equally well in extending the life of patients with melanoma, or not.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society